mouse monoclonal anti human cd82  (Proteintech)

Journal: Frontiers in Immunology

Article Title: CD82-associated exhausted CD8 + T cells define prognosis and immunotherapy resistance in colon cancer

doi: 10.3389/fimmu.2025.1731154

Figure Lengend Snippet: Expression distribution of CD82 in CD8 + T cell subsets analyzed by scRNA-seq. (A) UMAP visualization of cell types based on scRNA-seq data obtained from the GEO database. (B) Dot plot illustrating CD82 expression levels across different cell types in tumor and normal tissues from patients with colon cancer. (C) UMAP visualization of CD8 + T cell subsets based on scRNA-seq data obtained from the GEO database. (D) Dot plot illustrating CD82 expression levels across distinct CD8 + T cell subsets in tumor and normal tissues from patients with colon cancer.

Article Snippet: The following antibodies are used: CD82 (clone 1E7A4, 1:1000 dilution, Catalog No.: 66803-1-lg, Proteintech, USA), CD8 (clone 1G2B10, 1:2000 dilution, Cat. No.: 66868-1-Ig, Proteintech, USA), TIM-3 (clone D5D5RTM, 1:100 dilution, Catalog No.: 45208S, CST, USA), TCF1 (clone C63D9, 1:200 dilution, Catalog No.: 2203S, CST, USA), PD-1 (clone UMAB199, 1:100 dilution, Cat. No.: ZM0381, ZSGB-BIO, China), and PANCK (clone PDH09-10, 1:2000 dilution, Cat. No.: HA601138 , HUABio, China).

Techniques: Expressing

Journal: Frontiers in Immunology

Article Title: CD82-associated exhausted CD8 + T cells define prognosis and immunotherapy resistance in colon cancer

doi: 10.3389/fimmu.2025.1731154

Figure Lengend Snippet: Correlation analysis of CD82 expression with T cell exhaustion markers in TCGA-COAD. (A–H) Scatter plots illustrating the correlations between CD82 expression and T cell exhaustion–associated molecules in colon cancer tissues: (A) CTLA4, (B) FOXP3, (C) TIGIT, (D) CD8A, (E) MRC1 (CD206), (F) PDCD1 (PD-1), (G) HAVCR2 (TIM-3), and (H) LAG3. Correlations are assessed using Pearson’s correlation analysis (all P < 0.001).

Article Snippet: The following antibodies are used: CD82 (clone 1E7A4, 1:1000 dilution, Catalog No.: 66803-1-lg, Proteintech, USA), CD8 (clone 1G2B10, 1:2000 dilution, Cat. No.: 66868-1-Ig, Proteintech, USA), TIM-3 (clone D5D5RTM, 1:100 dilution, Catalog No.: 45208S, CST, USA), TCF1 (clone C63D9, 1:200 dilution, Catalog No.: 2203S, CST, USA), PD-1 (clone UMAB199, 1:100 dilution, Cat. No.: ZM0381, ZSGB-BIO, China), and PANCK (clone PDH09-10, 1:2000 dilution, Cat. No.: HA601138 , HUABio, China).

Techniques: Expressing

Journal: Frontiers in Immunology

Article Title: CD82-associated exhausted CD8 + T cells define prognosis and immunotherapy resistance in colon cancer

doi: 10.3389/fimmu.2025.1731154

Figure Lengend Snippet: Expression of CD82 in colon cancer tissue microarrays (TMA) and its prognostic significance. (A) Representative multiplex immunohistochemical (mIHC) staining and single-channel images of colon cancer TMAs (DAPI, blue; CK, purple; CD8, cyan; CD82, white). (B–D) Comparisons between normal and tumor tissues: (B) infiltration density of CD8 + T cells, (C) infiltration density of D82 + T cells, and (D) proportion of the CD8 + CD82 + subset within total CD8 + T cells. (E–G) Comparisons between epithelial and stromal regions within tumor tissues: (E) infiltration density of CD8 + T cells, (F) infiltration density of CD82 + T cells, and (G) proportion of the CD8 + CD82 + subset within total CD8 + T cells. (H–J) Kaplan–Meier survival curves for colon cancer patients stratified by: (H) CD8 + T cell infiltration density, (I) CD82 + T cell infiltration density, and (J) proportion of the CD8 + CD82 + subset within total CD8 + T cells. Optimal cutoff values for high and low expression groups are determined using X-tile software. P values for survival differences are calculated using the Kaplan–Meier method, and HR with 95%CI are estimated by univariate Cox proportional hazards regression analysis. ***P < 0.001; ****P < 0.0001.

Article Snippet: The following antibodies are used: CD82 (clone 1E7A4, 1:1000 dilution, Catalog No.: 66803-1-lg, Proteintech, USA), CD8 (clone 1G2B10, 1:2000 dilution, Cat. No.: 66868-1-Ig, Proteintech, USA), TIM-3 (clone D5D5RTM, 1:100 dilution, Catalog No.: 45208S, CST, USA), TCF1 (clone C63D9, 1:200 dilution, Catalog No.: 2203S, CST, USA), PD-1 (clone UMAB199, 1:100 dilution, Cat. No.: ZM0381, ZSGB-BIO, China), and PANCK (clone PDH09-10, 1:2000 dilution, Cat. No.: HA601138 , HUABio, China).

Techniques: Expressing, Multiplex Assay, Immunohistochemical staining, Staining, Software

Journal: Frontiers in Immunology

Article Title: CD82-associated exhausted CD8 + T cells define prognosis and immunotherapy resistance in colon cancer

doi: 10.3389/fimmu.2025.1731154

Figure Lengend Snippet: Co-expression of CD82 and exhaustion markers in colon cancer TMA and their prognostic significance. (A) Representative mIHC staining and single-channel images (DAPI, blue; CK, purple; CD8, cyan; CD82, white; TIM-3, green; PD-1, orange; TCF1, red). (B–D) Comparisons between normal and tumor tissues: (B) proportion of CD8 + CD82 + PD-1 + cells within CD8 + PD-1 + T cells, (C) proportion of CD8 + CD82 + PD-1 + TCF1 + cells within CD8 + PD-1 + TCF1 + T cells, and (D) proportion of CD8 + CD82 + TIM-3 + PD-1 + cells within CD8 + TIM-3 + PD-1 + T cells. (E–G ) Comparisons between epithelial and stromal regions within tumor tissues: (E) proportion of CD8 + CD82 + PD-1 + cells within CD8 + PD-1 + T cells, (F) proportion of CD8 + CD82 + PD-1 + TCF1 + cells within CD8 + PD-1 + TCF1 + T cells, and (G) proportion of CD8 + CD82 + TIM-3 + PD-1 + cells within CD8 + TIM-3 + PD-1 + T cells. (H–J) Kaplan–Meier survival curves for colon cancer patients stratified by: (H) proportion of CD8 + CD82 + PD-1 + cells within CD8 + PD-1 + T cells, (I) proportion of CD8 + CD82 + PD-1 + TCF1 + cells within CD8 + PD-1 + TCF1 + T cells, and (J) proportion of CD8 + CD82 + TIM-3 + PD-1 + cells within CD8 + TIM-3 + PD-1 + T cells. Optimal cutoff values for high and low expression groups are determined using X-tile software. P values for survival differences are calculated using the Kaplan–Meier method, and HR with 95%CI are estimated by univariate Cox proportional hazards regression analysis. *P < 0.05; ****P < 0.0001.

Article Snippet: The following antibodies are used: CD82 (clone 1E7A4, 1:1000 dilution, Catalog No.: 66803-1-lg, Proteintech, USA), CD8 (clone 1G2B10, 1:2000 dilution, Cat. No.: 66868-1-Ig, Proteintech, USA), TIM-3 (clone D5D5RTM, 1:100 dilution, Catalog No.: 45208S, CST, USA), TCF1 (clone C63D9, 1:200 dilution, Catalog No.: 2203S, CST, USA), PD-1 (clone UMAB199, 1:100 dilution, Cat. No.: ZM0381, ZSGB-BIO, China), and PANCK (clone PDH09-10, 1:2000 dilution, Cat. No.: HA601138 , HUABio, China).

Techniques: Expressing, Staining, Software

Journal: Frontiers in Immunology

Article Title: CD82-associated exhausted CD8 + T cells define prognosis and immunotherapy resistance in colon cancer

doi: 10.3389/fimmu.2025.1731154

Figure Lengend Snippet: scRNA-seq analysis and expression distribution of CD82 in CD8 + T-cell subpopulations following immunotherapy. (A, B) UMAP visualization of cell types (A) and CD82 expression distribution (B) based on scRNA-seq data from GEO datasets of colon cancer patients treated with immunotherapy. (C) Dot plot showing differences in CD82 expression levels across cell types between pathological complete response (pCR) and non-pCR groups after immunotherapy. (D, E) UMAP visualization of CD8 + T-cell subsets (D) and corresponding CD82 expression distribution (E) . (F) Scatter plot comparing CD82 expression levels among distinct CD8 + T-cell subsets between pCR and non-pCR groups post-immunotherapy. (G) Violin plot illustrating CD82 expression differences among CD8 + T-cell subsets between pCR and non-pCR groups following immunotherapy.

Article Snippet: The following antibodies are used: CD82 (clone 1E7A4, 1:1000 dilution, Catalog No.: 66803-1-lg, Proteintech, USA), CD8 (clone 1G2B10, 1:2000 dilution, Cat. No.: 66868-1-Ig, Proteintech, USA), TIM-3 (clone D5D5RTM, 1:100 dilution, Catalog No.: 45208S, CST, USA), TCF1 (clone C63D9, 1:200 dilution, Catalog No.: 2203S, CST, USA), PD-1 (clone UMAB199, 1:100 dilution, Cat. No.: ZM0381, ZSGB-BIO, China), and PANCK (clone PDH09-10, 1:2000 dilution, Cat. No.: HA601138 , HUABio, China).

Techniques: Expressing

Journal: Frontiers in Immunology

Article Title: CD82-associated exhausted CD8 + T cells define prognosis and immunotherapy resistance in colon cancer

doi: 10.3389/fimmu.2025.1731154

Figure Lengend Snippet: Single-cell regulatory network inference and clustering analysis of CD8 + T cells. (A) Heatmap showing regulon activity (AUCell AUC values) across CD8 + T-cell subsets. (B) Differentially expressed transcriptional regulators between pCR and non-pCR groups predicted to bind the promoter or enhancer regions of the CD82 gene. (C) Comparison of mRNA expression levels of candidate regulatory factors between pCR and non-pCR groups.

Article Snippet: The following antibodies are used: CD82 (clone 1E7A4, 1:1000 dilution, Catalog No.: 66803-1-lg, Proteintech, USA), CD8 (clone 1G2B10, 1:2000 dilution, Cat. No.: 66868-1-Ig, Proteintech, USA), TIM-3 (clone D5D5RTM, 1:100 dilution, Catalog No.: 45208S, CST, USA), TCF1 (clone C63D9, 1:200 dilution, Catalog No.: 2203S, CST, USA), PD-1 (clone UMAB199, 1:100 dilution, Cat. No.: ZM0381, ZSGB-BIO, China), and PANCK (clone PDH09-10, 1:2000 dilution, Cat. No.: HA601138 , HUABio, China).

Techniques: Activity Assay, Comparison, Expressing